echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > New Academician Xu Binghe in 2021: Put forward a new direction to solve the problem of tumor resistance

    New Academician Xu Binghe in 2021: Put forward a new direction to solve the problem of tumor resistance

    • Last Update: 2021-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to news from the Chinese Academy of Sciences website and the Chinese Academy of Engineering website on November 18, the results of the co-election of academicians of the two academies in 2021 were officially announced.


    Xu Binghe, male, born in February 1958, chief physician, professor, and doctoral supervisor


    "Don't treat advanced breast cancer as terminal disease


    Xu Binghe focuses on cutting-edge theories and technical research in the field of breast cancer, and leads the team to make a series of pioneering research work in breast cancer screening and early diagnosis, individualized treatment, and tumor resistance.


    The pyrrotinib he took the lead in research and development is China's first approved domestically-developed innovative drug HER-2 small molecule inhibitor, breaking the long-term monopoly of HER-2 targets by imported drugs and creating a precedent for rapid approval of clinical trials for marketing


    In the past five years, he has led the completion of China’s first approved listing of CDK4/6 inhibitor piperacillil, the first domestically produced CDK4/6 drug SHR6390, the first breast cancer ADC drug TDM-1, and the first China-Europe dual-reported domestic product.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.